# Initial Clinical and CBCT Outcomes of Enamel Matrix Derivative-Based Regenerative Therapy in Vertical Bone Defects

> **NCT06639555** · NA · COMPLETED · sponsor: **Tsvetalina Gerova-Vatsova** · enrollment: 48 (actual)

## Conditions studied

- Vertical Alveolar Bone Loss

## Interventions

- **PROCEDURE:** PRP( platelet rich plasma)
- **PROCEDURE:** EMD (Enamel Matrix Derivative)
- **PROCEDURE:** Guided Tissue Regeneration (barrier membrane)
- **PROCEDURE:** Guided Tissue Regeneration(barrier membrane and PRP)

## Key facts

- **NCT ID:** NCT06639555
- **Lead sponsor:** Tsvetalina Gerova-Vatsova
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-24
- **Primary completion:** 2023-02-15
- **Final completion:** 2023-08-15
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06639555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06639555, "Initial Clinical and CBCT Outcomes of Enamel Matrix Derivative-Based Regenerative Therapy in Vertical Bone Defects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06639555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*